Loading…
Loading…
5CV.DE (CureVac N.V.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
5CV.DE does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 5CV.DE and 80,000+ other tickers.
See exactly how 5CV.DE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 5CV.DE and 80,000+ other tickers.
CureVac N.V. is a biopharmaceutical entity operating in the clinical development phase, focused on pioneering revolutionary medicines utilizing messenger ribonucleic acid (mRNA) technology. Its portfolio includes prophylactic vaccines such as the mRNA-based candidate CV2CoV, currently in Phase 1 clinical trials for SARS-CoV-2. Another mRNA vaccine, CV7202, has successfully concluded Phase 1 trials for rabies, while CVSQIV is in Phase 1 development against influenza. The company is also advancing therapies for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and…
No recent news available.